Financial Performance: Co-Diagnostics reported a net loss of US$7.73 million, with revenue missing analyst estimates by 46%, while earnings per share exceeded expectations by 8%. The company's shares have increased by 16% over the past week.
Future Outlook and Risks: Revenue is projected to grow at an average rate of 76% annually over the next three years, significantly outpacing the Medical Equipment industry growth forecast of 8.2%. However, there are three warning signs regarding the company's performance that investors should be aware of.
CODX
$0.2461+Infinity%1D
Analyst Views on CODX
Wall Street analysts forecast CODX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CODX is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CODX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CODX is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.270
Low
1.50
Averages
1.50
High
1.50
Current: 0.270
Low
1.50
Averages
1.50
High
1.50
Maxim
NULL -> Buy
initiated
$1.50
2025-11-26
Reason
Maxim
Price Target
$1.50
2025-11-26
initiated
NULL -> Buy
Reason
Maxim initiated coverage of Co-Diagnostics with a Buy rating and $1.50 price target.
HC Wainwright & Co.
Yi Chen
Hold
Maintains
$1.5 → $1
2025-03-28
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$1.5 → $1
2025-03-28
Maintains
Hold
Reason
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
